Investigation oflipid-improving and pleiotrophic effects of pitavastati
Not Applicable
- Conditions
- Hpercholesterolemic patients with type II diabetes
- Registration Number
- JPRN-UMIN000019020
- Lead Sponsor
- Fukui University School of Medical Science
- Brief Summary
1) The pitavastatin treatment decreased LDL-C, sd-LDL-C, and CETP levels by 39%, 42%, and 23%, respectively. 2) Despite the absence of a significant association between CETP and LDL-C levels at baseline, baseline CETP levels and its percentage change were an independent positive determinant for the changes observed in LDL-C and sd-LDL-C levels.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with severe hepatic dysfunction 2) Patients with severe chronic renal dysfunction(serum Cr of 2.0 mg/dL or more) 3) Patients with severe cerebral vascular disease 4)Patients are judged as being inappropriate for this study by their own doctors 5) Patients are judged as being inappropriate for this study by investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method